Summary:
In this discussion from the 2024 IO360º conference, experts from Takeda, Johnson & Johnson Innovative Medicine, Natera and Friends of Cancer Research address ctDNA's potential for an emergent prognostic stratification marker, any insights it can offer into tumor evolution, and how it can be used for faster drug development.
For more information, visit IO360summit.com.
Speakers
Jeff Allen, PhD
CEO & President
Friends of Cancer Research (FOCR)
Matthew Silver, PhD
Head, Companion Diagnostics
Takeda
John Simmons, PhD
Global VP, Biopharma Partnerships
Natera
Reshma Patel
Director and Global Regulatory Lead
J&J Innovative Medicine
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.